跳至主要内容
临床试验/NCT00394537
NCT00394537已完成4 期

Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

Rabin Medical Center2 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2006年11月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
72
试验地点
2
主要终点
Heart Rate

研究概览

简要总结

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation.

We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients over 18 years old undergo fiberoptic bronchoscopy in our unit

排除标准

  • inability or refusal to give informed consent
  • bronchoscopy through an artificial airway
  • intolerance or allergy to the study drug
  • bradycardia (HR<60/min) or hypotension (systolic BP <100) at screening
  • pregnancy,
  • concomitant treatment with diltiazem or verapamil
  • intention to use propofol as the sedative agent for bronchoscopy.

结局指标

主要结局

Heart Rate

Systolic Blood Pressure

Diastolic Blood Pressure

Rate pressure product (HR*SBP/100)

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验